10 heart from ischemia-induced pathophysiology,” Hyperten- sion, vol. 51, no. 3, pp. 712–718, 2008. [63] Y. X. Zhao, H. Q. Yin, Q. T. Yu et al., “ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction,” Human Gene Therapy, vol. 21, no. 11, pp. 1545–1554, 2010. [64] Y. Ishiyama, P. E. Gallagher, D. B. Averill, E. A. Tallant, K. B. Brosnihan, and C. M. Ferrario, “Upregulation of angiotens- in-converting enzyme 2 after myocardial infarction by block- ade of angiotensin II receptors,” Hypertension, vol. 43, no. 5, pp. 970–976, 2004. [65] M. A. Kim, D. Yang, K. Kida et al., “Eﬀects of ACE2 inhibition in the post-myocardial infarction heart,” Journal of Cardiac Failure, vol. 16, no. 9, pp. 777–785, 2010. [66] M. P. Ocaranza, S. Lavandero, J. E. Jalil et al., “Angiotensin- (1–9) regulates cardiac hypertrophy in vivo and in vitro,” Journal of Hypertension, vol. 28, no. 5, pp. 1054–1064, 2010. [67] A. M. Kuklinska, B. Sobkowicz, R. Sawicki et al., “Apelin: a novel marker for the patients with ﬁrst st-elevation myocar- dial infarction,” Heart and Vessels, vol. 25, no. 5, pp. 363–367, 2010. [68] A. M. Tycinska, B. Sobkowicz, B. Mroczko et al., “The value of apelin-36 and brain natriuretic peptide measurements in patients with ﬁrst st-elevation myocardial infarction,” Clinica Chimica Acta, vol. 411, no. 23-24, pp. 2014–2018, 2010. [69] R. A. Weir, K. S. Chong, J. R. Dalzell et al., “Plasma apelin concentration is depressed following acute myocardial in- farction in man,” European Journal of Heart Failure, vol. 11, no. 6, pp. 551–558, 2009. [70] N. P. Kadoglou, S. Lampropoulos, A. Kapelouzou et al., “Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease- KOZANI STUDY,” Translational Research, vol. 155, no. 5, pp. 238–246, 2010. [71] J. C. Simpkin, D. M. Yellon, S. M. Davidson, S. Y. Lim, A. M. Wynne, and C. C. T. Smith, “Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemiareperfusion injury,” Basic Research in Cardiology, vol. 102, no. 6, pp. 518– 528, 2007. [72] C. C. Smith, M. M. Mocanu, J. Bowen et al., “Temporal changes in myocardial salvage kinases during reperfusion following ischemia: studies involving the cardioprotective ad- ipocytokine apelin,” Cardiovascular Drugs and Therapy, vol. 21, no. 6, pp. 409–414, 2007. [73] X. J. Zeng, L. K. Zhang, H. X. Wang, L. Q. Lu, L. Q. Ma, and C. S. Tang, “Apelin protects heart against ischemia/ reperfusion injury in rat,” Peptides, vol. 30, no. 6, pp. 1144– 1152, 2009. [74] C. H. Pan, J. L. Lin, L. P. Lai, C. L. Chen, S. K. Stephen Huang, and C. S. Lin, “Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial ﬁbrillation,” Febs Letters, vol. 581, no. 3, pp. 526–534, 2007. [75] M. Donoghue, H. Wakimoto, C. T. Maguire et al., “Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins,” Journal of Molecular and Cellular Cardiology, vol. 35, no. 9, pp. 1043– 1053, 2003. [76] P. T. Ellinor, A. F. Low, and C. A. MacRae, “Reduced apelin levels in lone atrial ﬁbrillation,” European Heart Journal, vol. 27, no. 2, pp. 222–226, 2006. [77] E. M. Kallergis, E. G. Manios, E. M. Kanoupakis et al., “Eﬀect of sinus rhythm restoration after electrical cardioversion on Cardiology Research and Practice apelin and brain natriuretic peptide prohormone levels in patients with persistent atrial ﬁbrillation,” American Journal of Cardiology, vol. 105, no. 1, pp. 90–94, 2010. [78] C. Falcone, M. P. Buzzi, A. D’Angelo et al., “Apelin plasma levels predict arrhythmia recurrence in patients with persis- tent atrial ﬁbrillation,” International Journal of Immunopa- thology and Pharmacology, vol. 23, no. 3, pp. 917–925, 2010. [79] K. Farkasfalvi, M. A. Stagg, S. R. Coppen et al., “Direct eﬀects of apelin on cardiomyocyte contractility and electrophysiol- ogy,” Biochemical and Biophysical Research Communications, vol. 357, no. 4, pp. 889–895, 2007. [80] S. Bodiga, J. C. Zhong, W. Wang et al., “Enhanced susceptibil- ity to biomechanical stress in ACE2 mice is prevented by loss of the p47phox nadph oxidase subunit,” Cardiovascular Research, vol. 91, no. 1, pp. 151–161, 2011. [81] G. Y. Oudit, Z. Kassiri, M. P. Patel et al., “Angiotensin II- mediated oxidative stress and inﬂammation mediate the age- dependent cardiomyopathy in ACE2 mice,” Cardiovas- cular Research, vol. 75, no. 1, pp. 29–39, 2007. [82] K. Yamamoto, M. Ohishi, T. Katsuya et al., “Deletion of angi- otensin-converting enzyme 2 accelerates pressure overload- induced cardiac dysfunction by increasing local angiotensin II,” Hypertension, vol. 47, no. 4, pp. 718–726, 2006. [83] A. J. Ferreira, V. Shenoy, Y. Qi et al., “Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac ﬁbrosis involving extracellular signal-regulated kin- ases,” Experimental Physiology, vol. 96, no. 3, pp. 287–294, 2011. [84] M. Flores-Munoz, L. M. Work, K. Douglas et al., “Angi- otensin-(1–9) attenuates cardiac ﬁbrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin Type 2 receptor,” Hypertension, vol. 59, no. 2, pp. 300–307, 2011. [85] M. Flores-Mun˜oz, N. J. Smith, C. Haggerty, G. Milligan, and S. A. Nicklin, “Angiotensin1–9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor,” Journal of Physiology, vol. 589, no. 4, pp. 939–951, 2011. [86] P. Xu, S. Sriramula, and E. Lazartigues, “ACE2/ANG-(1– 7)/mas pathway in the brain: the axis of good,” American Journal of Physiology, vol. 300, no. 4, pp. R804–R817, 2011. [87] L. Xiao, L. Gao, E. Lazartigues, and I. H. Zucker, “Brain- selective overexpression of angiotensin-converting enzyme 2 attenuates sympathetic nerve activity and enhances barore- ﬂex function in chronic heart failure,” Hypertension, vol. 58, no. 6, pp. 1057–1065, 2011. [88] Y. Feng, H. Xia, Y. Cai et al., “Brain-selective overexpression of human angiotensin-converting enzyme type 2 attenuates neurogenic hypertension,” Circulation Research, vol. 106, no. 2, pp. 373–382, 2010. [89] W. C. De Mello, “Angiotensin (1–7) reduces the cell volume of swollen cardiac cells and decreases the swelling-dependent chloride current. Implications for cardiac arrhythmias and myocardial ischemia,” Peptides, vol. 31, no. 12, pp. 2322– 2324, 2010. [90] W. C. De Mello, “Opposite eﬀects of angiotensin II and angiotensin (1–7) on impulse propagation, excitability and cardiac arrhythmias. Is the overexpression of ACE2 arrhyth- mogenic?” Regulatory Peptides, vol. 153, no. 1–3, pp. 7–10, 2009. [91] K. S. Chong, R. S. Gardner, J. J. Morton, E. A. Ashley, and T. A. McDonagh, “Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure,” European Journal of Heart Failure, vol. 8, no. 4, pp. 355–360, 2006.